Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group Portfolio 13F
Kahn Brothers Group Holdings Activity
- Portfolio value:
- $591.79M≈ (+$45M≈)
- Previous value:
- $546.73M≈
- # of changes:
- 31
- New positions:
- 0
- Reported for:
- 30 Jun 2020 (Q2)
- Latest filing date:
- 03 Aug 2020
Kahn Brothers Group has disclosed a total of 31 changes to the portfolio in the (2020 Q2) SEC report(s): increased the number of shares of 4, decreased the number of shares of 26 and completely sold out 1 position(s).
What stocks did Kahn Brothers Group buy in 2020 Q2?
What did Kahn Brothers Group invest in during 2020 Q2?
In the 2020 Q2 report(s) the following changes have been made to the top investments: (MRK) Merck & Company Inc (reduced shares -10.15%), (GSK) GlaxoSmithKline PLC ADR (reduced shares -1.66%), (BMY) Bristol-Myers Squibb Company (reduced shares -1.01%), (FLG) Flagstar Financial, Inc (reduced shares -1.37%) and (C) Citigroup Inc (reduced shares -0.86%).
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.